CBD and biologics: what 7 years on Rituximab taught me
Bottom line. I was on Rituximab from August 2016 to May 2023, seven years of infusions every six months. When I started researching how CBD would interact with it, I expected a complicated answer. The actual answer is counterintuitive: biologics like Rituximab, Humira, Enbrel, and Cosentyx are large-protein therapeutics cleared via proteolysis, not by liver CYP enzymes. CBD's CYP3A4/2C9/2C19 inhibition does not affect biologic clearance. That's the good news. What still matters: biologics suppress immune function in specific ways, and combining anything with a biologic is a conversation to have with your prescriber. Do not stop or adjust your biologic. Note: JAK inhibitors (Rinvoq, Xeljanz, Olumiant) and apremilast (Otezla) are NOT biologics, they're small molecules with CYP3A4 metabolism, and the interaction picture is different.
Key takeaways
- The counterintuitive good news: biologics are cleared via proteolysis, not CYP enzymes, CBD's CYP-pathway inhibition doesn't affect biologic clearance.
- What does still matter: biologics suppress immune function in specific ways, and your prescriber should know about any addition to your stack.
- The other drugs in your stack (methotrexate, prednisone) matter more pharmacokinetically than the biologic itself, check those pages.
- JAK inhibitors (Rinvoq, Xeljanz, Olumiant) are NOT biologics, they're small molecules with CYP3A4 metabolism, and the concern is real for those.
- Apremilast (Otezla) is also a small molecule, not a biologic, CYP3A4 metabolism applies there too.
What the science says
Why biologics aren't on the CBD-interaction lists
Biologics are large-protein therapeutics - most are monoclonal antibodies or recombinant fusion proteins. They're cleared via proteolysis: peptide breakdown by proteases throughout the body. They are not substrates of the liver CYP enzymes that metabolize small-molecule drugs. CBD's CYP3A4, CYP2C9, and CYP2C19 inhibition is therefore irrelevant to biologic clearance. Stöllberger 2023's 403-drug CBD-interaction review reflects this: biologics are not on the list of drugs with CYP overlap.
Why this is counterintuitive
Biologics feel "stronger" than oral pills — the weekly injection, the high cost, the precautions about live vaccines and infections. Patients reasonably assume "stronger drug equals bigger interaction risk." For CYP-pathway interactions specifically, that intuition is wrong. The class of mechanism (small molecule going through liver CYP enzymes) just doesn't apply to antibody-based therapeutics.
What still matters
Biologics suppress immune function in specific ways - TNF-α inhibition (Humira, Enbrel), IL-17 inhibition (Cosentyx, Taltz), IL-23 inhibition (Skyrizi, Stelara, Tremfya), and others. CBD has its own immune-modulating effects: Rodríguez Mesa 2021's systematic review of 24 articles documented Th1/Th17 downregulation across animal models. The clinical relevance of this overlap in humans is unstudied - but it's a question for your prescriber, not a reason to assume the combination is risky.
The mechanism (or absence of one)
A monoclonal antibody is a 150,000-dalton protein. It can't be a substrate of a liver CYP enzyme — that's not how proteases work. When you inject Humira, the adalimumab molecule binds TNF-α in circulation, is internalized by cells, and is degraded into amino acids by intracellular proteases. CBD's effect on CYP3A4 has no point of contact with that pathway.
The same is true for fusion proteins (Enbrel is a TNF-receptor-Fc fusion), pegylated antibody fragments (Cimzia), and recombinant cytokine antagonists across the biologic class. See the CYP450 mechanism explainer for the foundational pharmacology.
What this means for you
- Talk to your prescriber. Even though CYP-interaction isn't the concern, the immunosuppression context is. Your rheumatologist, dermatologist, or gastroenterologist should know about any addition to your stack.
- CBD doesn't replace your biologic. Biologics target specific cytokines and modify disease course. CBD has not been shown to do that. Reclaim does not recommend stopping or adjusting biologic therapy.
- The other drugs in your stack matter more. A common combination is biologic + methotrexate + sometimes prednisone. The CBD-interaction concerns shift to the small-molecule DMARDs - see our methotrexate and prednisone pages.
- Format choice. Topical CBD (the NANO roll-on) has minimal systemic absorption and is the lowest-systemic-exposure option if your prescriber wants to minimize total CBD exposure. The 50mg patches are isolate-based and drug-test-safe.
- Watch for liver enzymes. Some biologics (TNF inhibitors especially) require periodic LFT monitoring. CBD at high doses with concomitant valproate has elevated LFTs in clinical populations; at wellness doses (25–50mg/day) the concern is small but not zero.
JAK inhibitors are NOT biologics
Important clarification because JAK inhibitors are frequently conflated with biologics in patient discussions. Rinvoq (upadacitinib), Xeljanz (tofacitinib), and Olumiant (baricitinib) are small-molecule oral drugs — not antibodies. They are metabolized partly by CYP3A4. The CBD-CYP3A4 interaction concern that does not apply to antibody biologics does apply to JAK inhibitors.
The same is true for apremilast (Otezla), an oral PDE4 inhibitor - small molecule, CYP3A4-metabolized, not a biologic despite the autoimmune indication. If you're on a JAK inhibitor or Otezla, the relevant page is the drug-interactions hub and the CYP450 explainer; dedicated per-drug JAK pages are coming in a future build.
Biologic brand-name reference
| Brand | Generic | Class | CBD CYP concern? |
|---|---|---|---|
| Humira | Adalimumab | TNF inhibitor | No (proteolysis) |
| Enbrel | Etanercept | TNF inhibitor | No (proteolysis) |
| Cimzia | Certolizumab | TNF inhibitor | No (proteolysis) |
| Remicade | Infliximab | TNF inhibitor | No (proteolysis) |
| Cosentyx | Secukinumab | IL-17 inhibitor | No (proteolysis) |
| Taltz | Ixekizumab | IL-17 inhibitor | No (proteolysis) |
| Stelara | Ustekinumab | IL-12/23 inhibitor | No (proteolysis) |
| Skyrizi | Risankizumab | IL-23 inhibitor | No (proteolysis) |
| Tremfya | Guselkumab | IL-23 inhibitor | No (proteolysis) |
| Rinvoq | Upadacitinib | JAK inhibitor (NOT biologic) | Yes — CYP3A4 |
| Xeljanz | Tofacitinib | JAK inhibitor (NOT biologic) | Yes — CYP3A4 |
| Olumiant | Baricitinib | JAK inhibitor (NOT biologic) | Yes — CYP3A4 |
| Otezla | Apremilast | Small-molecule PDE4 (NOT biologic) | Yes — CYP3A4 |
Frequently asked questions
Can I take CBD if I'm on Humira, Enbrel, or Cosentyx?
I was on a biologic for 7 years. Here's what I actually found: the CYP-pathway concern that gets raised for most drug interactions simply doesn't apply to biologics. They're cleared by proteolysis, peptide breakdown, not by liver CYP enzymes. That's the good news. The conversation your prescriber still needs to have is about immunosuppression context: biologics change how your immune system works, and your rheumatologist or dermatologist should know about any addition to your stack, CBD included.
What about CBD and Rinvoq or Xeljanz (JAK inhibitors)?
This is an important distinction that trips people up. JAK inhibitors are NOT biologics, they're small-molecule oral drugs metabolized partly by CYP3A4. The CBD-CYP3A4 concern that doesn't apply to antibody biologics does apply to JAK inhibitors. If you're on Rinvoq, Xeljanz, or Olumiant, the interaction picture is meaningfully different. Talk to your prescriber, and see the drug-interactions hub for related pages.
Will CBD make my biologic less effective?
No documented mechanism for this. Biologics work by binding specific cytokines or receptors, Rituximab targets CD20 on B cells, for example. CBD's action is at receptor and CYP enzyme levels that don't intersect with those biologic targets. CBD does have immune-modulating effects in animal models (Th1/Th17 downregulation per Rodríguez Mesa 2021), but the clinical relevance of that overlap in humans is not characterized. I never noticed my biologic becoming less effective when I used CBD.
Can CBD reduce the side effects of my biologic?
There's no clinical evidence for this, and I wouldn't frame it that way. Some patients report CBD helps with infusion-day fatigue or sleep disruption, those are uncontrolled observations, not data. What I can say: CBD helped with my general symptom management during years on Rituximab. Whether that's related to the biologic or just the disease load, I can't say. If your biologic side effects are unmanageable, that's a conversation to have with your prescriber directly, CBD is downstream of that.
I'm on a biologic + methotrexate + folate. Does CBD interact with the combination?
This was my actual stack for years. The biologic part is fine, proteolysis clearance, no CYP overlap. The methotrexate part is where the pharmacokinetic concern lives: CBD inhibits CYP3A4, which partially metabolizes MTX. See the methotrexate page for that detail. Folate-pathway interactions with CBD haven't been quantified clinically.
References
- Stöllberger C, Finsterer J. (2023). Interactions between cannabidiol and commonly used prescription drugs. PMID 37541924
- Bansal S et al. (2023). Cannabidiol effects on the pharmacokinetics of substrates of cytochrome P450 enzymes. PMID 37313955
- Cuñetti L et al. (2024). Cannabidiol elevated cyclosporine and mycophenolate levels in a kidney transplant patient. PMID 38212169
- Rodríguez Mesa XM et al. (2021). Therapeutic prospects of cannabinoids in the immunomodulation of prevalent autoimmune diseases. PMID 34030476
- Iffland K, Grotenhermen F. (2017). An update on safety and side effects of cannabidiol. PMID 28861514
Related reading
Some related pages are still being written.